Lincoln Pharmaceuticals Management

Management criteria checks 4/4

Lincoln Pharmaceuticals' CEO is Mahendrabhai Patel, appointed in Jun 2018, has a tenure of 5.92 years. total yearly compensation is ₹3.32M, comprised of 99.1% salary and 0.9% bonuses, including company stock and options. directly owns 7.93% of the company’s shares, worth ₹960.31M. The average tenure of the management team and the board of directors is 8.8 years and 28.8 years respectively.

Key information

Mahendrabhai Patel

Chief executive officer

₹3.3m

Total compensation

CEO salary percentage	99.1%
CEO tenure	5.9yrs
CEO ownership	7.9%
Management average tenure	8.8yrs
Board average tenure	28.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mahendrabhai Patel's remuneration changed compared to Lincoln Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹873m
Sep 30 2023	n/a	n/a	₹808m
Jun 30 2023	n/a	n/a	₹769m
Mar 31 2023	₹3m	₹3m	₹729m
Dec 31 2022	n/a	n/a	₹714m
Sep 30 2022	n/a	n/a	₹674m
Jun 30 2022	n/a	n/a	₹667m
Mar 31 2022	₹3m	₹3m	₹694m
Dec 31 2021	n/a	n/a	₹709m
Sep 30 2021	n/a	n/a	₹668m
Jun 30 2021	n/a	n/a	₹647m
Mar 31 2021	₹3m	₹3m	₹623m
Dec 31 2020	n/a	n/a	₹586m
Sep 30 2020	n/a	n/a	₹560m
Jun 30 2020	n/a	n/a	₹540m
Mar 31 2020	₹2m	₹2m	₹514m
Dec 31 2019	n/a	n/a	₹510m
Sep 30 2019	n/a	n/a	₹492m
Jun 30 2019	n/a	n/a	₹453m
Mar 31 2019	₹2m	₹2m	₹487m
Dec 31 2018	n/a	n/a	₹470m
Sep 30 2018	n/a	n/a	₹495m
Jun 30 2018	n/a	n/a	₹458m
Mar 31 2018	₹2m	₹2m	₹346m

Compensation vs Market: Mahendrabhai's total compensation ($USD39.80K) is about average for companies of similar size in the Indian market ($USD39.30K).

Compensation vs Earnings: Mahendrabhai's compensation has been consistent with company performance over the past year.

CEO

Mahendrabhai Patel (69 yo)

5.9yrs

Tenure

₹3,322,000

Compensation

Mr. Mahendrabhai Gulabdas Patel, B.A, LLB serves as Managing Director of Lincoln Pharmaceuticals Ltd. Mr. Patel has varied experience of chemicals, steel, finance etc. Mr. Patel handles corporate planning...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mahendrabhai Patel	MD & Whole Time Director	5.9yrs	₹3.32m	7.93% ₹ 960.3m
Darshit Shah	Chief Financial Officer	5.2yrs	₹1.18m	no data
Trusha Shah	Company Secretary & Compliance Officer	1.5yrs	₹228.00k	no data
Ashish Patel	Head of Sales & Marketing and Whole Time Director	11.6yrs	₹53.35k	10.6% ₹ 1.3b
Hashmukhbhai Patel	Whole Time Director	29.3yrs	₹3.33m	1.87% ₹ 225.9m
Munjal Patel	Whole Time Director	no data	₹3.44m	13.13% ₹ 1.6b
Sanjay Bhatt	Senior Manager of Operation	no data	no data	no data
C. Kapadia	Head of Sales & Admin	no data	no data	no data
Amit Dwivedi	Group Marketing Manager	no data	no data	no data
Sachin Kapoor	Head of H R D	no data	no data	no data
K. Sompura	Head of Finance	no data	no data	no data
Dhaval Gandhi	Head of Information Technology	20.3yrs	no data	no data

8.8yrs

Average Tenure

48yo

Average Age

Experienced Management: 531633's management team is seasoned and experienced (8.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mahendrabhai Patel	MD & Whole Time Director	29.3yrs	₹3.32m	7.93% ₹ 960.3m
Ashish Patel	Head of Sales & Marketing and Whole Time Director	9.5yrs	₹53.35k	10.6% ₹ 1.3b
Hashmukhbhai Patel	Whole Time Director	29.3yrs	₹3.33m	1.87% ₹ 225.9m
Munjal Patel	Whole Time Director	9.5yrs	₹3.44m	13.13% ₹ 1.6b
Rajnikant Patel	Non-Executive Director	29.3yrs	no data	3.78% ₹ 457.6m
Kishorbhai Shah	Non-Executive Chairman	28.8yrs	no data	2.39% ₹ 289.3m
Saurin Jagdish Parikh	Independent Non-Executive Director	6.2yrs	no data	no data

28.8yrs

Average Tenure

65yo

Average Age

Experienced Board: 531633's board of directors are seasoned and experienced ( 28.8 years average tenure).

Lincoln Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Whole Time Director recently bought ₹15m worth of stock

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Whole Time Director recently bought ₹5.0m worth of stock

Recent updates

Now 22% overvalued

Now 24% overvalued

Lincoln Pharmaceuticals Limited Announces Resignation of Meha Patel as Non-Executive Independent women Director

Insider recently bought ₹13m worth of stock

Third quarter 2024 earnings released: EPS: ₹14.00 (vs ₹10.79 in 3Q 2023)

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 08, 2024

Second quarter 2024 earnings released: EPS: ₹13.81 (vs ₹11.84 in 2Q 2023)

Lincoln Pharmaceuticals Limited Declares Dividend for the Financial Year 2022-23

Upcoming dividend of ₹1.50 per share at 0.3% yield

Lincoln Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Whole Time Director recently bought ₹15m worth of stock

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

First quarter 2024 earnings released: EPS: ₹9.49 (vs ₹7.49 in 1Q 2023)

Whole Time Director recently bought ₹15m worth of stock

Full year 2023 earnings released: EPS: ₹36.40 (vs ₹34.63 in FY 2022)

Lincoln Pharmaceuticals Limited Approves the Resignation of Anand A. Patel from the Position of Whole Time Director as Well as Director of the Company

Lincoln Pharmaceuticals Limited to Report Q4, 2023 Results on May 25, 2023

Whole Time Director recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹10.79 (vs ₹8.79 in 3Q 2022)

Lincoln Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 09, 2023

Lincoln Pharmaceuticals Limited Informs About Demise of Shri Ishwarlal Ambalal Patel Independent Director

MD & Whole Time Director recently bought ₹20m worth of stock

MD & Whole Time Director recently bought ₹9.9m worth of stock

Less than half of directors are independent

Lincoln Pharmaceuticals Limited Appoints Trusha Shah as Company Secretary and Compliance Officer

Lincoln Pharmaceuticals Limited Approves to Declare Dividend for the Financial Year 2021-22

Upcoming dividend of ₹1.50 per share

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited Proposes to Declare Dividend for the Financial Year 2021-2022

Lincoln Pharmaceuticals Limited, Annual General Meeting, Sep 30, 2022

Lincoln Pharmaceuticals Limited Approves Appointment of Anand A. Patel as an Additional and Whole Time Director

First quarter 2023 earnings released: EPS: ₹7.49 (vs ₹8.85 in 1Q 2022)

Lincoln Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

Lincoln Pharmaceuticals Limited Announces Resignation of Niren A. Desai as Company Secretary / Compliance Officer, with Effect from July 19, 2022

Board Member recently bought ₹20m worth of stock

Whole Time Director recently bought ₹20m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2022

Less than half of directors are independent

Whole Time Director recently bought ₹6.0m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Lincoln Pharmaceuticals Limited to Report Q3, 2022 Results on Feb 10, 2022

Board Member recently bought ₹8.2m worth of stock

Lincoln Pharmaceuticals Limited (BSE:531633) acquired plant in Mehsana, Gujarat for INR 300 million.

MD & Whole Time Director recently bought ₹15m worth of stock

Investor sentiment improved over the past week

Board Member recently bought ₹11m worth of stock

Whole Time Director recently bought ₹12m worth of stock

First quarter 2022 earnings released: EPS ₹8.85 (vs ₹7.63 in 1Q 2021)

Whole Time Director recently bought ₹16m worth of stock

Full year 2021 earnings released: EPS ₹31.11 (vs ₹25.72 in FY 2020)

Lincoln Pharmaceuticals Limited Recommends Dividend for the Year Ended March 31, 2021

New 90-day high: ₹250

Whole Time Director recently bought ₹8.3m worth of stock

Whole Time Director recently bought ₹30m worth of stock

New 90-day low: ₹216

Third quarter 2021 earnings released: EPS ₹6.74 (vs ₹5.46 in 3Q 2020)

Whole Time Director recently bought ₹20m worth of stock

Second quarter 2021 earnings released: EPS ₹10.46

Revenue and earnings beat expectations

Lincoln Pharmaceuticals Limited (BSE:531633) agreed to acquire remaining 1.42% stake in Lincoln Parenteral Limited for INR 3.7 million.

New 90-day high: ₹256

Lincoln Pharmaceuticals Limited Launches Chewable Vitamin C + Zinc Tablet for the Markets in India

Lincoln Pharmaceuticals Limited to Report Q4, 2021 Results on May 30, 2021

MD & Whole Time Director recently bought ₹2.4m worth of stock

New 90-day high - ₹245

First quarter earnings released

Lincoln Pharmaceuticals Limited to Report Q1, 2021 Results on Aug 20, 2020

New 90-day high - ₹208